A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors.

► Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor.
► Two cases with recurrent glioblastoma and anaplastic meningioma.
► No severe adverse events have been observed using BNCT.
► BNCT has a possibility of a safe palliative therapy for malignant brain tumors.